Navigation Links
Transplanted Liver Lining Cells May Cure Hemophilia
Date:2/14/2008

Experiments in mice may lead to new treatments for the disease, study suggests

THURSDAY, Feb. 14 (HealthDay News) -- Scientists have shown that transplanting healthy liver cells into mice with hemophilia enables the animals to produce a critical clotting factor missing in humans with type A hemophilia.

The breakthrough finding may lead the way to a cure for type A hemophilia, the most common type of the disease, researchers believe.

"We were able to verify what cell type in the body can make factor VIII, which is deficient in hemophilia A," said lead researcher Dr. Sanjeev Gupta, a professor of hepatology at Albert Einstein College of Medicine in New York City.

"In addition, we were able to replace the cells that line the liver and, in that way, we were able to cure the disorder in mice," Gupta said.

In the study, Gupta's team worked with a mouse model of hemophilia. They transplanted healthy liver endothelial cells into the livers of these mice, according to the report in the Feb. 14 online issue of the Journal of Clinical Investigation.

Three months after transplanting the cells, the number of healthy cells had increased and were producing factor VIII in amounts sufficient to cure their hemophilia, the researchers found.

Given these results, researchers can start to focus on where factor VIII is made in the human body and how things can go wrong with its production, Gupta said.

"From the treatment point of view, we can now begin to direct our attention to these particular cells and find the most effective way to cure this disorder in people," Gupta said.

There are several different ways to treat hemophilia A, Gupta said. These include injecting the missing clotting factor, replenishing blood from time to time, or correcting the gene through gene therapy or cell transplantation.

"What we have done in this work seems to be more promising than any of the other modalities," Gupta said. "This is the first time a cure has been achieved with cell therapy. That opens up new directions in treating the condition."

Hemophilia A affects one in 10,000 males and can cause uncontrolled bleeding that can lead to disability or death. It is commonly been associated with British and Russian nobility but affects many others. Cures for hemophilia have ranged from faith healing by the Russian monk Rasputin in the early 20th century to clinical trials using gene therapy, but none of these approaches have amounted to a cure.

One expert thinks a lot more study is needed before this technique can be tried in patients.

"If successful in other animal models, this approach could add another option of treatment for patients with severe hemophilia, though one would have to weigh the risk-benefit ratio," said Dr. Prasad Mathew, from the Ted R. Montoya Hemophilia Center at the University of New Mexico.

More information

For more about hemophilia, visit the U.S. National Library of Medicine.



SOURCES: Sanjeev Gupta, M.D., professor, hepatology, Albert Einstein College of Medicine, New York City; Prasad Mathew, M.D., Ted R. Montoya Hemophilia Center, University of New Mexico, Albuquerque; Feb. 14, 2008, Journal of Clinical Investigation, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Circulating fats kill transplanted pancreas cells, study shows
2. Transplanted Bone Marrow Cells Aid Nerve Regeneration
3. Advanced Age No Bar to Liver Transplant
4. Researchers Find Better Way to Deliver Blood Thinner
5. Federal research plan to determine nanotech risks fails to deliver
6. Liver cancer marker could yield blood test for early detection
7. Blood Marker Might Help Spot Early Liver Cancer
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Diet Change Can Curb Fatty Liver Disease
10. US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
11. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transplanted Liver Lining Cells May Cure Hemophilia
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: